Companies Dominating the Acute Myeloid Leukemia Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis International AG
- Celgene Corporation
- Bristol-Myers Squibb Company
- Amgen Inc.
- AbbVie Inc.
- Eli Lilly and Company
- GlaxoSmithKline plc
- Sanofi-Aventis (Genzyme Corporation)
- Sunesis Pharmaceutical Inc.
The acute myeloid leukemia market consists of several key players who are launching various strategic initiatives to expand their market position in the acute myeloid leukemia industry.
Browse Key Market Insights with Data Illustration:
In the News
- Novartis International AG announced that it was successfully acquiring Cadent Therapeutics, a biotechnology company in clinical development for the manufacture of medicines for nervous and psychiatric diseases. The objective of this acquisition was to expand the range of medicines provided by Novartis for cancer and gene therapy, in particular AML therapies.
- Bristol-Myers Squibb announced that its product, Onureg, had been approved by the FDA for maintenance therapy of AML in patients who were completely cured after aggressive chemotherapy. This medicine is the first and only oral medicine to be approved by the FDA for this use.
